Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç, Lucia Pantani, Maria Teresa Petrucci, Meletios A Dimopoulos, Luca Dozza, Bronno van der Holt, Sonja Zweegman, Stefania Oliva, Vincent H. J. van der Velden, Elena Zamagni, Giuseppe A. Palumbo, Francesca Patriarca, Vittorio Montefusco, Mónica Galli, Vladimír Maisnar, Barbara Gamberi, Markus Hansson, Angelo Belotti, Luděk Pour, Paula F. Ypma, Mariella Grasso, Alexsandra Croockewit, Stelvio Ballanti, Massimo Offidani, Iolanda Donatella Vincelli, Renato Zambello, Anna Marina Liberati, Niels Frost Andersen, Annemiek Broijl, Rossella Troia, Anna Pascarella, Giulia Benevolo, Mark‐David Levin, Gerard M.J. Bos, Heinz Ludwig, Sara Aquino, Anna Morelli, Ka Lung Wu, Rinske Boersma, Roman Hájek, Marc Durian, Peter A. von dem Borne, Tommaso Caravita di Toritto, Thilo Zander, Christoph Driessen, Giorgina Specchia, Anders Waage, Peter Gimsing, Ulf‐Henrik Mellqvist, Marinus van Marwijk Kooy, Monique C. Minnema, Caroline M.P.W. Mandigers, Anna Maria Cafro, Angelo Palmas, Susanna Carvalho, Andrew Spencer, Mario Boccadoro, Pieter Sonneveld (2020). Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. , 7(6), DOI: https://doi.org/10.1016/s2352-3026(20)30099-5.